Murphy Andrew J's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Mar 15, 2024
- Accession no.
- 0001968202-24-000086
- Filed
- Mar 15, 2024
- Trade date
- Mar 13-14, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 16 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.53M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Murphy Andrew JCIK 0001796226 | Officer (EVP Research) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2024 | Common Stock | MOption exerciseAcquired | +20,000 | $399.66 | +$7,993,200 | 68,306 | Direct | |
| Mar 13, 2024 | Common Stock | FTax withholdingDisposed | −14,217 | $971.82 | −$13,816,364.94 | 54,089 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −182 | $951.92F2 | −$173,249.44 | 53,907 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −444 | $952.40F3 | −$422,865.6 | 53,463 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −576 | $953.77F4 | −$549,371.52 | 52,887 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −870 | $954.66F5 | −$830,554.2 | 52,017 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −545 | $955.54F6 | −$520,769.3 | 51,472 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −1,108 | $956.34F7 | −$1,059,624.72 | 50,364 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −730 | $957.35F8 | −$698,865.5 | 49,634 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −477 | $958.34F9 | −$457,128.18 | 49,157 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −512 | $959.36F10 | −$491,192.32 | 48,645 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −47 | $961.74 | −$45,201.78 | 48,598 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −1 | $962.87 | −$962.87 | 48,597 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −78 | $965.51F11 | −$75,309.78 | 48,519 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −17 | $966.30 | −$16,427.1 | 48,502 | Direct | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −196 | $968.20F12 | −$189,767.2 | 48,306 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2024 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 20,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents volume-weighted average price of sales of 182 shares of Company stock on March 14, 2024 at prices ranging from $951.89 to $951.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents volume-weighted average price of sales of 444 shares of Company stock on March 14, 2024 at prices ranging from $952.00 to $952.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Represents volume-weighted average price of sales of 576 shares of Company stock on March 14, 2024 at prices ranging from $953.30 to $953.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
Represents volume-weighted average price of sales of 870 shares of Company stock on March 14, 2024 at prices ranging from $954.01 to $954.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
Represents volume-weighted average price of sales of 545 shares of Company stock on March 14, 2024 at prices ranging from $955.02 to $955.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F7
Represents volume-weighted average price of sales of 1,108 shares of Company stock on March 14, 2024 at prices ranging from $956.08 to $956.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F8
Represents volume-weighted average price of sales of 730 shares of Company stock on March 14, 2024 at prices ranging from $957.02 to $957.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F9
Represents volume-weighted average price of sales of 477 shares of Company stock on March 14, 2024 at prices ranging from $958.06 to $958.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F10
Represents volume-weighted average price of sales of 512 shares of Company stock on March 14, 2024 at prices ranging from $959.13 to $959.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F11
Represents volume-weighted average price of sales of 78 shares of Company stock on March 14, 2024 at prices ranging from $965.26 to $965.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F12
Represents volume-weighted average price of sales of 196 shares of Company stock on March 14, 2024 at prices ranging from $968.15 to $968.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.